X
Software Functionality Revealed in Detail
We’ve opened the hood on every major category of enterprise software. Learn about thousands of features and functions, and how enterprise software really works.
Get free sample report

Compare Software Solutions
Visit the TEC store to compare leading software solutions by funtionality, so that you can make accurate and informed software purchasing decisions.
Compare Now
 

 lost drugs


Managing the Aches and Pains of Long Cycle Times: Automating Controls for Pharmaceutical Manufacturers
One of the biggest challenges (or business pain points) for pharmaceutical manufacturers (or life sciences companies) is the long cycles that are required for

lost drugs  diminishing profits due to lost market share and a shortened product life cycle. A delayed or lengthened cycle time can seriously affect the return on investment (ROI) for a given new drug or product. What can help? A software solution that implements automated controls that address compliance issues, including 21 CFR Part 11. How does 21 CFR Part 11 relate to product R&D and approvals? For all of the processes involved in getting a drug to market, strict policies must be established and followed by a

Read More


Software Functionality Revealed in Detail

We’ve opened the hood on every major category of enterprise software. Learn about thousands of features and functions, and how enterprise software really works.

Get free sample report
Compare Software Solutions

Visit the TEC store to compare leading software by functionality, so that you can make accurate and informed software purchasing decisions.

Compare Now

Documents related to » lost drugs

Impressive Enterprise Resource Planning Solution Gets A Little Help From Its Friends


Despite impressive product depth and breadth (for instance, customer relationship management [CRM], workflow, traceability, and quality management are provided natively), Strategic Systems International (SSI) has longstanding partnerships with several best-of-breed specialists.

lost drugs   Read More

The Executive Guide to Contract and Chargeback Management


Life sciences companies are struggling to manage large group purchase organization (GPO) contracts, process chargeback submissions, and ensure that pricing policies comply with regulatory requirements. Costs and risks are escalating as these demands outstrip the capabilities of existing systems. Learn how contract and chargeback management solutions can help you maximize growth while limiting regulatory risk.

lost drugs   Read More

Business-to-business Price Segmentation-Outlined and Explained


The central premise of price segmentation, especially in business-to-business environments, is that pricing should be consistent for similar deals. The process quantifies similarity by empirically determining which deal circumstances affect price response, enabling companies to benchmark prices against similar transactions.

lost drugs   Read More

Talent Management: The New Business Imperative


Studies and statistics suggest that, because of demographic trends, companies will soon face a shortage of talent. In response, many companies have begun adopting processes and tools to more effectively recruit, retain, and develop talent. At the top of the list are human capital management (HCM) and talent management systems. Find out how these new technologies can help your company survive the coming talent crunch.

lost drugs   Read More

The State of Global Clinical Research Trials


New technologies and changing economic conditions have triggered a number of changes in the pharmaceuticals, life sciences, and biotech sectors. Increased global sales of life sciences products and growing demand for drugs present drug industry companies with a host of opportunities. However, the mandate for clinical trials has led to considerable inflation in their research and development (R&D) expenditure. The resolution lies in using emerging markets as an alternative to conduct these trials. Thanks to new technologies, the cloud, and social media/online portals, the pharmaceuticals, life sciences and biotech sectors can make the most of the emerging opportunities. Learn how.

lost drugs   Read More

How to Use Projects to Master Asset Management


IFS co-founder Ulf Stern and senior advisor Anders Wilhelmsson discuss how project management functionality that is tightly integrated with enterprise asset management (EAM) and asset lifecycle management (ALM) tools is essential to executives of asset-intensive industries. Lacking this integration, valuable asset data is lost and asset utilization cannot be maximized.

lost drugs   Read More

Enterprise IP PBX Security: System Evaluation Across Multiple Levels


Security is a vital consideration when evaluating enterprise Internet protocol (IP) telecommunications solutions. In addition to delivering business benefits, a voice over IP (VoIP) system may also become a target for unauthorized users, and must be secured against threats. Indeed, if threats and vulnerabilities are not addressed, the results can be devastating with respect to lost productivity, resources, and reputation.

lost drugs   Read More

Robust Systems are Built from the Bottom Up


Information technology infrastructure takes a back seat to applications investments for lack of a cost justification method. However, the infrastructure systems are breaking down in public; bringing significant attention to an issue that has been set aside far too long.

lost drugs   Read More

Acronyms Can Simplify Your Life, or Drive You Insane


Acronyms seem really convenient, at first. It’s great using ERP instead of enterprise resource planning, for example. You save precious time (not typing enterprise resource planning a million times) and there’s no way your reader won’t understand what ERP means, right? Well, for ERP this may be true, but all acronyms are not as tidy as they appear. What about BPM, for example? Does it

lost drugs   Read More

U.S. Crypto Laws Relaxed, but Not Enough to Enable Commerce


The revisions the Department of Commerce has announced for U.S. export controls on encryption products will not be enough for U.S. crypto products to gain International acceptance. The U.S. crypto market will fail to reach its revenue potential, and overseas companies and International crypto markets will continue to bask lavishly from bungled U.S. export policy.

lost drugs   Read More